Analysis of anti-clostridium difficile activity of thuricin CD, vancomycin, metronidazole, ramoplanin, and actagardine, both singly and in paired combinations

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 6, 2013, Pages 2882-2886

  Mathur, Harsh ^a   O'Connor, Paula M ^b,c   Hill, Colin ^a,c   Cotter, Paul D ^b,c   Ross, R Paul ^b,c  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b TEAGASC FOOD RESEARCH CENTRE   (Ireland)

^c UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ACTAGARDIN; METRONIDAZOLE; RAMOPLANIN; THURICIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CLOSTRIDIUM DIFFICILE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BACTERIOCINS; CLOSTRIDIUM DIFFICILE; DEPSIPEPTIDES; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; PEPTIDES; VANCOMYCIN;

EID: 84877872661     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00261-13     Document Type: Article

References (37)

1. Vollaard EJ, Clasener HA. 1994. Colonization resistance. Antimicrob. Agents Chemother. 38:409-414.
2. Shanahan F. 2002. The host-microbe interface within the gut. Best Pract. Res. Clin. Gastroenterol. 16:915-931.
3. O'Hara AM, Shanahan F. 2006. The gut flora as a forgotten organ. EMBO Rep. 7:688-693.
4. Blaser MJ. 2011. Antibiotic overuse: Stop killing the beneficial flora. Nature 476:393-394.
5. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. 2007. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel disease. Proc. Natl. Acad. Sci. U. S. A. 104:13780-13785.
6. Cramer JP, Burchard GD, Lohse AW. 2008. Old dogmas and new perspectives in antibiotic-associated diarrhea. Med. Klin. (Munich) 103:325-338. (In German.)
7. Gerding DN, Muto CA, Owens, RC, Jr. 2008. Treatment of Clostridium difficile infection. Clin. Infect. Dis. 46:S32-S42.
8. Vardakas KZ, Polyzos KA, Patouni K, Rafailidis PI, Samonis G, Falagas ME. 2012. Treatment failure and recurrence of Clostrdium difficile infection following treatment with vancomycin or metronidazole: A systematic review of the evidence. Int. J. Antimicrob. Agents 40:1-8.
9. Al-Nassir WN, Sethi AK, Nerandzic MM, Bobulsky GS, Jump RL, Donskey CJ. 2008. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin. Infect. Dis. 47:56-62.
10. Mezoff E, Mann EA, Hart KW, Lindsell CJ, Cohen MB. 2011. Clostridium difficile infection and treatment in the pediatric inflammatory bowel disease population. J. Pediatr. Gastroenterol. Nutr. 52:437-441.
11. Choi HK, Kim KH, Lee SH, Lee SJ. 2011. Risk factors for recurrence of Clostridium difficile infection: Effect of vancomycin-resistant enterococci colonization. J. Korean Med. Sci. 26:859-864.
12. Musher DM, Logan N, Bressler AM, Johnson DP, Rossignol JF. 2009. Nitazoxanide versus vancomycin in Clostridium difficile infection: A randomized, double-blind study. Clin. Infect. Dis. 48:e41-e46.
13. Pépin J, Valiquette L, Gagnon S, Routhier S, Brazeau I. 2007. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after emergence of NAP1/027. Am. J. Gastroenterol. 102:2781-2788.
14. Chung CH, Wu CJ, Lee HC, Yan JJ, Chang CM, Lee NY, Chen PL, Lee CC, Hung YP, Ko WC 2010. Clostridium difficile infection at a medical centre in southern Taiwan: Incidence, clinical features and prognosis. J. Microbiol. Immunol. Infect. 43:119-125.
15. Rea MC, Dobson A, O'Sullivan O, Crispie F, Fouhy F, Cotter PD, Shanahan F, Kiely B, Hill C, Ross RP. 2011. Effect of broad and narrow spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. Proc. Natl. Acad. Sci. U. S. A. 108:4639-4644.
16. Lagrotteria D, Holmes S, Smieja M, Smaill F, Lee C. 2006. Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficileassociated diarrhea. Clin. Infect. Dis. 43:547-552.
17. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH. 2010. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect. Control Hosp. Epidemiol. 31:431-455.
18. Cheng AC, Ferguson JK, Richards MJ, Robson JM, Gilbert GL, McGregor A, Roberts S, Korman TM, Riley TV. 2011. Australasian Society for Infectious Diseases guidelines for the diagnosis and treatment of Clostridium difficile infection. Med. J. Aust. 194:353-358.
19. Bauer MP, Kuijper EJ, van Dissel JT. 2009. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): Treatment guidance document for Clostridium difficile infection (CDI). Clin. Microbiol. Infect. 15:1067-1079.
20. Bacon AE, McGrath S, Fekety R, Holloway WJ. 1991. In vitro synergy studies with Clostridium difficile. Antimicrob. Agents Chemother. 35: 582-583.
21. Hames A, Perry JD, Gould FK. 2009. In vitro effect of metronidazole and vancomycin in combination on Clostridium difficile. J. Antimicrob. Chemother. 63:1076.
22. Hall MJ, Middleton RF, Westmacott D. 1983. The fractional inhibitory concentration (FIC) index as a measure of synergy. J. Antimicrob. Chemother. 11:427-433.
23. Larson KC, Belliveau PP, Spooner LM. 2011. Tigecycline for the treatment of severe Clostrdium difficile infection. Ann. Pharmacother. 45: 1005-1010.
24. Patrick Basu P, Dinani A, Rayapudi K, Pacana T, Shah NJ, Hampole H, Krishnaswamy NV, Mohan V. 2010. Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: A prospective pilot trial. Therap. Adv. Gastroenterol. 3:221-225.
25. Rea MC, Sit CS, Clayton E, O'Connor PM, Whittal RM, Zheng J, Vederas JC, Ross RP, Hill C. 2010. Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile. Proc. Natl. Acad. Sci. U. S. A. 107:9352-9357.
26. Boakes S, Ayala T, Herman M, Appleyard A, Dawson MJ, Cortes J. 2012. Generation of an actagardine A variant library through saturation mutagenesis. Appl. Microbiol. Biotechnol. 95:1509-1517.
27. Boakes S, Cortes J, Appleyard AN, Rudd BAM, Dawson MJ. 2009. Organisation of the genes encoding the biosynthesis of actagardine and engineering of a variant generation system. Mol. Microbiol. 72:1126-1136.
28. Peláez T, Alcacá L, Alonso R, Martín-Lopez A, García-Arias V, Marín M, Bouza E. 2005. In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole. Antimicrob. Agents Chemother. 49: 1157-1159.
29. Freeman J, Baines S, Jabes D, Wilcox M. 2005. Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostrdium difficile infection. J. Antimicrob. Chemother. 56:717-725.
30. Citron DM, Merriam CV, Tyrell KL, Warren YA, Fernandez H, Goldstein EJ. 2004. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria. Antimicrob. Agents Chemother. 47:2334-2338.
31. McCafferty DG, Cudic P, Frankel BA, Barkallah S, Kruger RG, Li W. 2002. Chemistry and biology of the ramoplanin family of peptide antibiotics. Biopolymers 66:261-284.
32. Jabes D, Candiani C, Riva S, Mosconi G. 2003. Superior efficacy of short treatment duration of ramoplanin over vancomycin in the hamster model of C. difficile associated colitis, abstr B328. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
33. Field D, Begley M, O'Connor PM, Daly KM, Hugenholtz F, Cotter PD, Hill C, Ross RP. 2012. Bioengineered nisin A derivatives with enhanced activity against both Gram positive and Gram negative pathogens. PLoS One 7:e46884. doi:10.1371/journal.pone.0046884.
34. Orhan G, Bayram A, Zer Y, Balci I. 2005. Synergy tests by E test and checkerboard methods of antimicrobial combinations against Brucella mellitensis. J. Clin. Microbiol. 43:140-143.
35. Naghmouchi K, Belguesmia Y, Baah J, Teather R, Drider D. 2011. Antibacterial activity of class I and IIa bacteriocins combined with polymyxin E against resistant variants of Listeria monocytogenes and Escherichia coli. Res. Microbiol. 162:99-107.
36. Wong SSY, Woo PCY, Luk WK, Yuen KY. 1999. Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest. Diagn. Microbiol. Infect. Dis. 34:1-6.
37. Aspevall O, Lundberg A, Burman LG, Akerlund T, Svenungsson B. 2006. Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish university hospital. Antimicrob. Agents Chemother. 50:1890-1892.